Doctors can often identify signs of a melanoma through a visual examination of a patient’s skin, by using a dermoscope or other tools. But additional information is sometimes needed to make a precise diagnosis, according to SciBase, a medical tech company based in Stockholm, Sweden—which has developed a device it says provides exactly that.
2023
FDA Approves Melphalan Hepatic Delivery System for Adult Patients With Unresectable Hepatic-Dominant Metastatic Uveal Melanoma
On August 14, the U.S. Food and Drug Administration (FDA) approved the HEPZATO KIT, a melphalan hepatic delivery system, as a liver-directed treatment for adult patients with metastatic uveal melanoma and unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.
Atkins Assesses the Differences Between Immunotherapy Strategies in Advanced Melanoma
During a Targeted Oncology™ Case-Based Roundtable™ event, Michael B. Atkins, MD, discussed with participants what factors influence the choice of first-line immunotherapy for a patient with BRAF–wild-type metastatic melanoma.
Study Identifies a Causal Relationship Between Psoriasis and Cutaneous Melanoma
Psoriasis increases the risk of cutaneous melanoma, according to the findings of a new study.